Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study
Xia et al., ChiCTR2000029741
Early results from a very small trial, reported within the application for a later trial. Very minimal details are provided, but we include this as the earliest published result. For COVID-19 patients with pneumonia the viral negative conversion rate was 50% (5/10) with CQ versus 20% (3/15) with lopinavir/ritonavir.
Standard of Care (SOC) for COVID-19 in the study country,
China, is
average with
moderate efficacy for approved treatments
1.
This study is excluded in the after exclusion results of meta
analysis:
minimal details provided.
|
risk of no viral clearance, 37.5% lower, RR 0.62, p = 0.17, treatment 5 of 10 (50.0%), control 12 of 15 (80.0%), NNT 3.3.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Xia et al., 11 Feb 2020, retrospective, China, preprint, 1 author.
